GSK (NYSE:GSK) (NYSE:GSK) is a global research-based biopharmaceutical company headquartered in London, United Kingdom. It develops and commercializes a broad portfolio of prescription medicines, vaccines and specialty products guided by a science-led approach. The company’s pharmaceutical pipeline spans respiratory, HIV/infectious disease, oncology and immuno-inflammation therapies, while its vaccine division focuses on preventative treatments for diseases such as shingles, meningitis and malaria. GSK also co-owns ViiV Healthcare, a specialist HIV company formed in partnership with Pfizer, reflecting its commitment to addressing persistent and emerging health challenges worldwide.
Founded in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK draws on a heritage dating back to the 19th century. Over the decades, the company has refined its strategic focus through acquisitions, divestments and joint ventures. In 2022, GSK completed the separation of its consumer healthcare business, now operating as Haleon, allowing the core company to concentrate resources on pharmaceuticals and vaccines. This evolution underscores GSK’s pursuit of innovation, operational efficiency and targeted growth in high-impact therapeutic areas.
GSK maintains a global presence, with operations in more than 150 countries and a network of research and manufacturing sites across Europe, North America, Asia and Latin America. The company invests heavily in R&D, operating multiple research centers that collaborate with academic institutions, biotech firms and public health organizations. Under the leadership of CEO Emma Walmsley, appointed in 2017, GSK has prioritized digital transformation, sustainability and patient access to medicines. Its governance structure includes a board of directors and executive committee tasked with driving long-term value, ethical standards and compliance in every market it serves.
With an extensive development pipeline and a portfolio of established and emerging therapies, GSK aims to deliver solutions that address critical health needs across both mature and developing markets. The company’s vaccine innovations, including a next-generation influenza platform and an adjuvant technology leveraged in pandemic preparedness, highlight its role in global immunization efforts. As GSK continues to advance new drug candidates and strengthen collaborations, it seeks to balance scientific ambition with the practical goal of improving outcomes for millions of patients worldwide.
